Unless they’re covering me in a cloud of norovirus particles. When the violent expelling of liquid starts somewhere other ...

Anyone who thought (as I did) that the worst was over for Moderna's COVID-19 vaccine sales will be especially bothered by the company's update. But while Moderna's near-term prospects don't look ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's challenges in the vaccine market, and the probability of success with its ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier. David, thanks for joining me today.

The world’s second-richest person launched the Courage and Civility Award in 2021 to support philanthropists—and Eva Longoria ...

“I have tried to live in a world that does not see color but have only succeeded in living in a world that does not see me,” he ... in developing Moderna’s Covid-19 vaccine.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

The number of wasted COVID-19 vaccines under the national government’s vaccination program went beyond the “acceptable” ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

Moderna Receives $590M From HHS to Develop Bird Flu Vaccine By India Edwards HealthDay Reporter TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS ...